When patients and voters like you speak up on health care issues, you make it possible for millions of Americans to experience savings at the pharmacy counter and to lead healthier and more productive lives.
Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and working with policymakers on measures to make it feasible to bring more manufacturing back to the United States.
AAM opposes abuses of the patent system by brand-name drug companies, and we advocate for patent reform that lends itself to timely patient access to safe, effective and more-affordable medicines for patients in the United States.
AAM works with federal and state level governments to promote best practices aimed at increasing the use of generic medicines and saving taxpayer money. These efforts include rapid responses to anti-substitution stories, advocating for specific generic substitution laws and general education.
AAM promotes and protects access to affordable medicines in trade agreements and represents these interests before the U.S. Trade Representative, the Department of Commerce, Congress, The White House and other stakeholders.